Skip to main content

Table 2 Subgroup analysis stratified by injectable and oral Marsdenia tenacissima extract

From: Oral and injectable Marsdenia tenacissima extract (MTE) as adjuvant therapy to chemotherapy for gastric cancer: a systematic review

Outcome Injectable MTE subgroup Oral MTE subgroup Interaction P value
No. of studies Estimate (95% CI) I2 No. of studies Estimate (95% CI) I2
Response to treatment 12 POR 2.02 (1.58–2.58) 0% 2 POR 1.94 (1.04–3.60) 0% 0.90
Performance status 7 POR 2.94 (1.99–4.34) 0% 1 POR 4.31 (1.89–9.84) 0% 0.41
Leukopenia 12 RR 0.68 (0.57–0.82) 42% 3 RR 0.57 (0.36–0.90) 44% 0.48
Thrombocytopenia 11 RR 0.67 (0.49–0.93) 33% 2 RR 0.42 (0.11–1.59) 69% 0.50
Nausea/vomiting 9 RR 0.82 (0.71–0.94) 0% 2 RR 0.47 (0.29–0.78) 0% 0.04
Hepatic injury 9 RR 0.83 (0.62–1.12) 19% 2 RR 0.61 (0.39–0.95) 0% 0.25
  1. Note: Subgroup analysis was unavailable for anemia, diarrhea, constipation, kidney injury, peripheral neurotoxicity, and oral mucosal lesions because all trials that assessed these outcomes used injectable Marsdenia tenacissima extract
  2. Abbreviations: MTE Marsdenia tenacissima extract; POR proportional odds ratio; RR risk ratio; CI confidence interval